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A venous bypass technique (BP) that does not require the use 
of systemic anticoagulation is used routinely at our institution 
in all adult patients during the anhepatic phase of liver 
transplantation (L T). Complete cardiopulmonary profiles were 
obtained in a subset of 28 consecutive cases. During the 
anhepatic phase while on bypass, mean arterial pressure, 
central venous pressure, and pulmonary arterial wedge pressure 
were maintained at prehepatectomy levels. Oxygen consumption 
fell secondary to a decrease in temperature and the removal of 
the liver. Consequently, cardiac index fell without an increase 
in arterial-venous O2 content difference, reflecting adequate 
tissue oxygenation. Compared with 63 patients in a previous 
series given L T without bypass (NBP), the 57 total BP patients 
experienced better postoperative renal function (p < 0.001), 
required less blood use during surgery (p < 0.01), and had 
better survival 30 days after LT. The equivalency of 90-day 
survival in these groups results from the lack of effect of BP 
on the long-term survival of patients considered at high risk 
for metabolic reasons. BP patients at high risk for technical 
considerations, however, survived LT whereas NBP patients 
did not. BP offers other advantages important in establishing 
L T as a service-oriented procedure. 
THE DRAMA TIC IMPACT of cyclosporine on survival following liver transplantation has been widely 
reported. I - 4 Yet despite extensive experience with the 
operation during the preceding 17 years, only a few 
important technical improvements were reported to 
have significantly enhanced survival.3•5- s In fact, during 
the first 3 years in which cyclosporine was used, mortality 
related to a difficult intraoperative course remained a 
disturbing problem. For the most part, these difficulties 
centered around the anhepatic phase and repeatedly 
underscored the need for an effective method of venous 
bypass. The need for the development of new method-
ology was clearly demonstrated by the severe penalty 
imposed by the requirement for systemic heparinization 
during a trial of venous bypass using conventional 
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techniques in 12 patients during the summer of 1982. 
The development in the laboratory of a heparin-less 
bypass system was reported by Denmark et al. 9 and the 
initial clinical trial using these techniques presented by 
Griffith et al. 1o The effectiveness of this method of 
venous bypass is the subject of the current study. 
Methods 
Between February 15, 1983 and March 22, 1984, a 
total of 57 adults were treated with orthotopic hepatic 
transplantation at the University of Pittsburgh using 
venous bypass without the use of systemic anticoagula-
tion. The technique used is essentially that described by 
Griffith with only minor changes. In particular, the use 
of a 9-mm Gott (Argyle Division, Sherwood Medical, 
St. Louis, MO) shunt for cannulation of the portal vein 
and a 7-mm shunt for the axillary vein has proven to 
be a more satisfactory alternative to the reverse situation 
described in the previous paper. 1O The femoral vein is 
cannulated with a 7-mm Gott shunt via a cut-down on 
the saphenous vein. 
The femoral and portal vein cannulae come together 
at a metal Y-connector, which is in turn attached to 
%-inch polyvinyl chloride tubing (Tygon, Norton In-
dustrial Plastics, Akron, OH), which leads to a conical, 
centripetal force pump head (Bio-Medicus, Inc., Min-
netonka, MN). The return flow is to the axillary vein. 
The system is a completely closed one that does not 
require a reservoir in the circuit. An electromagnetic 
flow meter (Bio-Medicus, Inc., Minnetonka, MN) is 
attached to the outflow of the pump head. Flows are 
maintained at 1000 ml/min or more, a rate that was 
defined in the laboratory as that below which formation 
of clots and platelet aggregates were more likely to 
occur. Once bypass flow has been established at a 
satisfactory rate, the vena cava below and above the 
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native liver is clamped and the liver excised. Hemostasis 
in the liver bed can then be obtained, if necessary. The 
portal venous and lower caval systems are decompressed 
so that, in general, venous hypertension does not exac-
erbate the bleeding at this point. 
The revascularization of the new liver then occurs in 
a routine manner.} The usual sequence involves sewing 
the upper vena cava anastomosis followed by the lower 
caval anastomosis. The liver is then flushed out with 
300 to 500 ml of cold saline via the portal vein cannula. 
This step flushes the preservation fluid, high in potassium, 
out of the liver. It also fills and evacuates air from the 
vena cava. The patient is placed in a Trendelenberg 
position and the fluid allowed to escape through the 
anterior part of the lower caval anastomosis. Whether 
the portal vein or the arterial anastomosis is completed 
next is dependent upon a number of variables. In 
general, 60 to 80 minutes are allowed for the anastomoses 
before some flow is returned to the liver. In those 
situations where clamping the portal vein side of the 
bypass circuit (in order to perform the portal vein 
anastomosis) results in dropoff of the flow below 1000 
ml/min, the bypass should be discontinued to minimize 
the chance of thrombus formation. If the arterial anas-
tomosis has been completed by this time, the arterial 
and caval clamps can be released prior to decannulating 
the portal vein and coming off bypass. The proper choice 
for sequencing these steps must be determined by the 
surgeon for each situation. 
Intraoperative Monitoring 
Cardiopulmonary data were obtained using a multiple 
lumen pulmonary artery catheter. In the subset of 
patients for whom complete profiles were obtained, a 
four-lumen catheter employing an oximeter at the distal 
tip (Oximetrix, Inc., Mountain View, CA) was employed. 
Complete cardiopulmonary profiles were obtained prior 
to the induction of anesthesia, after anesthesia had been 
established but before significant fluid losses had oc-
curred, just before initiating the bypass, during the 
bypass, and shortly after revascularization of the liver. 
Oxygen consumption was calculated using the Fick 
equation. Coagulation data were obtained routinely on 
all patients using a thromboelastogram. 
Renal Function 
The mean serum creatinine of all patients was deter-
mined immediately prior to undergoing liver transplan-
tation and then after surgery. Comparisons were made 
between the preoperative values and the highest post-
operative value within 72 hours of transplantation. The 
means were compared using the paired and unpaired 
Student's t-tests. The number of patients in the bypass 
and non-bypass groups who were not on dialysis prior 
to surgery but who required dialysis within the first 7 
days of transplantation were determined and compared 
using the chi square test. Patients with preoperative 
renal failure or preoperative requirements for dialysis 
were eliminated from this latter comparison. A subset 
of 30 consecutive patients were monitored for urine 
output during surgery. 
Blood Use 
Figures regarding the number of units of blood com-
ponents used during transplantation operations were 
kept by the Central Blood Bank of Pittsburgh. Mean 
blood use was compared using the Student's unpaired 
t-test and the median values by the rank-sum test. 
Mortality and Survival 
Life-table analysis was used to determine survival of 
the various groups and these values compared by the 
method of Greenwood 11 using the standard errors of the 
survival possibilities for each interval. Minimum follow-
up on all patients was 35 days. A total of 63 and 57 
patients in the non-bypass and bypass groups, respec-
tively, were used for survival calculations. 
Heparinized Bypass from June 15-September 6, 1982 
Twelve patients, nine of whom were adults, underwent 
liver transplantation using a conventional bypass system 
that necessitated systemic anticoagulation with heparin. 
These are the subject of a brief comparison with the 
current system. 
Results 
From March 9, 1980 to March 22, 1984, a total of 
129 adult patients, 12 at the University of Colorado and 
117 at the University of Pittsburgh, underwent orthotopic 
hepatic transplantation. Sixty-three of these patients 
were treated without the use of any venous bypass 
technique, nine with a bypass technique utilizing systemic 
anticoagulation, and 57 utilizing venous bypass without 
systemic anticoagulation. The indications for transplan-
tation are shown in Table 1. 
Cardiopulmonary Data 
Flow in the bypass system ranged from 1 to 13 liters 
per minute, with a mean of 2.77 (±0.827) L/min. 
Average bypass time was 91.2 (±19.7) minutes. Complete 
cardiopulmonary data were obtained in 28 consecutive 
cases between March 30 and August 16, 1983. These 
data are presented in Table 2. The pre-bypass values are 
the means (±SD) of those obtained after induction of 
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TABLE 1. Indications for Liver Transplantation 
Postnecrotic cirrhosis 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Malignancy 
Budd-Chiari syndrome 
Secondary biliary cirrhosis 
Alpha-I-antitrypsin deficiency 
Wilson's disease 
Miscellaneous 
Total 
No 
Bypass 
25 
12 
6 
6 
4 
4 
4 
o 
2 
63 
Bypass 
17 
16 
10 
5 
0 
I 
I 
4 
3 
57 
anesthesia but before devascularization of the native 
liver. The bypass data are the means (±SD) of the data 
obtained during the actual anhepatic state while patients 
were undergoing venous bypass. These data show that 
the oxygen consumption (V02/M2) fell secondary to a 
decrease in temperature (T) and removal of the liver. 
Consequently, cardiac index (CI) fell without an increase 
in arterial-venous oxygen content difference (a-vD02), 
reflecting adequate tissue oxygenation. In addition, sys-
Variable 
T(°C) 
HR (bpm) 
MAP (mmHg) 
PAO (torr) 
CVP (mmHg) 
pC02 (torr) 
p02 (torr) 
Sa02 
Pv02 (torr) 
Sv02 (torr) 
Hgb (gldl) 
pHa 
CI (L/min· m2) 
SI 
RVSWI 
LVSWI 
SVRI 
PVRI 
a-vOO2 
V02/m2 
O2 transport 
TABLE 2. Cardiopulmonary Profiles 
Pre-bypass Bypass 
Mean SD Mean SD 
34.9 .98 33.8 1.16 
85.6 14.3 84.1 14.2 
75 17.1 83 17.6 
12.0 4.2 10.5 3.3 
9.9 4.4 9.2 4.9 
33.3 5.2 29.9 4.8 
380 92.4 398 91.6 
0.9854 0.0915 0.9896 0.0160 
65.5 16.3 70.8 21.5 
0.904 0.0598 0.927 0.0496 
9.62 1.16 10.2 1.42 
7.42 0.07 7.40 0.08 
4.37 1.44 3.44 1.09 
51.7 15.9 41.4 13.6 
5.11 3.21 3.52 3.17 
43.4 14.3 39.7 11.4 
443.7 233 660 366 
34.3 23.9 44.1 39.1 
2.04 .81 1.87 .59 
83.0 24.7 61.7 20.5 
1087 391 917 342 
P 
0.0002 
0.0125 
0.0079 
0.0121 
0.0109 
0.0009 
HR-heart rate; MAP-mean arterial pressure; PAG-pulmonary arterial 
wedge pressure; CVP-central venous pressure; pC02-partiai pressure 
carbon dioxide; p02-partial pressure oxygen; Sa02-arterial oxygen sat-
uration; Pv02-mixed venous oxygen pressure; Sv02-oxygen saturation 
pulmonary artery; Hgb-hemoglobin; pHa-arteriai pH; CI-cardiac index; 
SI-saturation index; RVSWI-right ventricular stroke work index; 
L VSWI-left ventricular stroke work index; SVRI-systemic vascular re-
sistance; PVRI-pulmonary vascular resistance; a-vOO2-arterial-venous 
oxygen content difference; VOum2-oxygen consumption. 
TABLE 3. Comparisons of Postoperative Renal Function 
No Bypass Bypass 
(N = 38) (N = 48) P 
Preoperative mean 
serum creatinine 1.65 ± 1.85 1.23 ± 1.43 
Postoperative mean P < 0.005 P < 0.05 
serum creatinine'" 3.00 ± 2.70 1.51 ± 1.27 
Mean change + 1.29 ± 1.95 +0.35 ± 0.90 p < 0.001 
Patients requiring 
dialysis during 
first postoperative 
week 6 0 P < 0.01 
.. Maximum value in first 3 postoperative days. 
temic vascular resistance (SVRI) fell significantly while 
mean arterial pressure (MAP), central venous pressure 
(CVP), and pulmonary arterial wedge pressures (PAO) 
did not change. 
Renal Function 
Table 3 reveals that renal function changed to a 
significant degree in both the patients with bypass and 
those without. Of note is that the increase in creatinine 
in the non-bypass group (+ 1.29 ± 1.95 mg/dl) is signif-
icantly greater (p < 0.001) than that seen in the bypass 
group (+0.35 ± 0.90 mg/dl). Complete anuria or marked 
oliguria was not an infrequent occurrence during the 
anhepatic phase in the previous experience with liver 
transplantation.3 Urine output during the anhepatic 
phase is maintained quite well in patients on bypass, 
with a mean urine flow of 187 (±249) ml/hour (range 
0-1360 ml/hour). Complete anuria was experienced in 
only one patient in the bypass group. In addition, 
marked hematuria, a postoperative occurrence in 10% 
to 15% of non-bypass adults, has been absent in the 
bypass group. 
Blood Use 
Data were compared for the total blood use during 
the transplant operation of 36 patients using venous 
bypass and a total of 43 without bypass. These data are 
presented in Table 4. The range in blood use of the 
non-bypass group was 3 to 251 units of packed red 
blood cells (PRBC) and was 5 to 157 units PRBC for 
Range 
Median 
Mean 
TABLE 4. Packed Red Blood Cell Requirement (Units) 
No Bypass Bypass 
(N = 43) (N = 36) p 
3-251 5-157 
27 16 p < 0.05 
32.7 ± 25.1 18.9 ± 8.0 p < 0.01 
Vol. 200 • No.4 VENOUS BYPASS IN LIVER TRANSPLANTATION 527 
the bypass group. The median blood use was 27 for the 
non-bypass group versus 16 for the bypass group (p 
< 0.05). Mean blood use was calculated by eliminating 
10 cases from each group. The five lowest and five 
highest numbers were withdrawn from the comparison 
because of the wide standard deviations, which did not 
allow for a representative comparison. The mean loss 
in the non-bypass group (32.7 ± 25.1 units PRBC) was 
higher (p < 0.01) than in the bypass group (18.9 ± 8.0 
units PRBC). An examination of Table 5 reveals that 
the mean blood loss with the heparinized bypass system 
was 53.1 ± 33 units PRBC with a range of 10 to 94 
units, significantly higher than the non-heparin bypass 
group (p < 0.001) or the non-bypass group (p < 0.05). 
Hospital Stay 
The number of days that patients remained in the 
hospital from the date of transplantation to the date of 
discharge are compared for the two groups in Table 6. 
The mean length of stay for the non-bypass group was 
56.4 (±35.1) days versus 51.1 (±28.9) days for those 
bypassed (p> 0.50). If all patients whose prolonged 
hospital stay was secondary to retransplantation were 
eliminated, the length of stay is still not different between 
these groups (p > 0.05). 
Bypass and Retransplantation 
The requirements for retransplantation are similar 
between the bypass and non-bypass groups, with 14 
patients in the former and 12 in the latter group 
requiring retransplantation. The survival following re-
transplantation is not significantly different at either 1 
month or 3 months after surgery. 
Mortality and Survival 
The actuarial survival curves for the non-bypass and 
bypass groups are shown in Figure 1. All patients in 
each group were followed for a minimum of 30 days 
after surgery and included 57 bypass and 63 non-bypass 
patients. Survival at 30 days was 91.1 % for the bypass 
group compared to 73% for the non-bypass group (p 
< 0.004). At 90 days, however, survival in the bypass 
group (73.2%) was not significantly different from that 
in the group without bypass (68.3%) (p > 0.05). Six of 
the patients in whom bypass was not used died on the 
operating table. The one operative death occurring in 
the bypass group was the result of an irreparable injury 
to the donor liver. That patient experienced no cardi-
odynamic instability during the hepatic revascularization. 
Table 5 reveals that three of nine patients bypassed 
using anticoagulation died in the operating room, and 
a fourth expired before 30 days. Only two of the nine 
TABLE 5. Experience with Venous Bypass using Systemic 
Anticoagulation, June 25, 1982 to September 6, 1982 
(Nine Adult Patients Undergoing 11 Operations) 
Operative deaths 3(9 (33%) 
Mean blood loss (units PRBClt 
Range 
53.1 ± 33.0* ± SD 
10-94 
30-day survival 
90-day survival 
5(9 (55.6%) 
2(9 (22.2%):t: 
* p < 0.05 compared to no bypass; p < 0.01 compared to non-
heparinized bypass. 
t PRBC-packed red blood cells. 
:t: Each living, 22 months after surgery. 
patients survived beyond 90 days and both were living 
22 months after surgery at the conclusion of this study. 
An examination of the causes of death in both groups 
reveals that they are quite similar. Sepsis, accompanied 
by mUltiple organ failure and, in particular, liver failure, 
was universal. In an attempt to understand why the 
significant difference in survival at 30 days was no longer 
present by 90 days, patients were classified into three 
groups. Status 1 patients are stable, relatively low-risk 
candidates, including those who are primarily outpatient 
care-dependent with only infrequent hospitalization. 
Nutritional status is good to excellent. A history of 
significant esophageal variceal bleeding but with rapid 
recovery would not exclude a patient from this group. 
Status 2 patients are those who require frequent hospi-
talization, who have advanced cirrhosis with moderate 
to severe ascites, occasional episodes of grade 3 to 4 
encephalopathy, recurrent episodes of variceal bleeding 
with attendant worsening of encephalopathy, and those 
whose life-style has been significantly altered by their 
disease. A history of previous major abdominal surgery, 
which would increase a candidate's intraoperative risk, 
would lead to a change in status from category 1 to 2. 
Status 3 patients were the very high-risk group. The 
criteria for which patients would be placed into this 
group are either metabolic or technical. All of the 
metabolic group patients require hospitalization, most 
in the intensive care unit. All have frequent bouts of 
grade 3 to 4 encephalopathy. Malnutrition is severely 
advanced; ascites and hypoalbuminemia are extreme. 
Some patients with acute hepatic decompensation sec-
ondary to toxic agents were placed under this category 
by virtue of their emergent situation, In the current 
Range 
Median 
Mean 
TABLE 6. Postoperative Hospital Stay 
(Patients Discharged in Pittsburgh) 
No Bypass Bypass 
(N = 30) (N = 37) 
16-145 days 21-165 days 
51 days 42 days 
56.4 ± 35.1 51.1 ± 28.9 
p> 0.05 
p > 0.50 
----------------------------------------------------------------------------------
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FIG. 1. Ninety-<iay actuarial survival for liver transplants performed with and without venous bypass. 
study, nine of the 26 Status 3 patients (four in the non-
bypass, five in the bypass group) were in stage 4 coma 
in an intensive care unit setting with severe renal 
dysfunction and requiring ventillatory support. Technical 
considerations that would require a Status 3 classification 
include a previous portacaval shunt, thrombosed portal 
vein, or mUltiple previous abdominal surgeries involving 
the liver or bile ducts. Four patients in the non-bypass 
and two in the bypass group were so classified. 
A breakdown of the survival curves based on this 
assignment of status is depicted in Figures 2, 3, and 4. 
In Status 1 patients, eight of nine non-bypass and all 
six bypass patients remain alive at the end of the study. 
Among 41 Status 2 patients without bypass, 30-day and 
90-day survival is 88% and 76%, respectively, compared 
to 97.2% and 85.2% for the same intervals among 38 
Status 2 patients treated with bypass. Thirteen patients 
were classified as Status 3 in both the non-bypass and 
bypass groups. Survival at 30 days was 31 % for the non-
bypass group compared to 61.5% of the bypass group 
(p < 0.01). However, mortality in the bypass group 
between 30 and 90 days was significantly higher (p 
< 0.05) than in the non-bypass group, so that survival 
by 90 days was 31 % and nine per cent in the non-
bypass and bypass groups, respectively (p < 0.05). 
Among the four patients classified as Status 3 in the 
non-bypass group because of technical considerations, 
three were operative deaths and the fourth died in less 
than 48 hours after surgery. Both of the technical Status 
3 bypass patients are alive 2 and 6 months after surgery. 
Discussion 
Despite the landmark improvements in survival rates 
among liver transplant recipients provided by the intro-
duction of cyclosporine, 1-4 early mortality and morbidity 
related to a difficult intraoperative course remained a 
significant problem. Approximately 50% of all patients 
who died within 1 year following transplantation were 
lost by the end of the first 30 days. In addition, operative 
mortality among the first 63 adult patients treated with 
cyclosporine was 9.5%. 
Historical Background 
Physiologically and sometimes technically, the most 
difficult period of the actual transplant operation is the 
anhepatic phase, when the native liver has been removed. 
Cross-clamping the portal vein and the abdominal por-
tion of the inferior vena cava causes several problems. 
The first results from the loss of return to the central 
venous system of the large volume of caval flow from 
the abdomen. The second stems from the hypertension 
that develops in the obstructed portal and systemic 
venous beds. The third occurs at the time of liver 
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revascularization when stagnant blood from the ob-
structed venous beds, sometimes rich in acid and potas-
sium, is suddenly returned into the systemic circulation. 
Previous studies revealed that the typical response to 
the anhepatic phase is a 50% reduction in cardiac output 
accompanied by a marked increase in systemic vascular 
resistance. '2 More recent experience has shown that the 
response can be quite variable. In young, otherwise 
healthy individuals it is similar to what occurs in severe 
acute hypovolemia. Although arterial blood pressure is 
fairly well maintained, cardiac output is reduced to as 
much as one-fifth of the preocclusion levels while sys-
temic vascular resistance increases three to four fold. 
Patients with preexisting cardiac dysfunction, or older 
patients, do not tolerate the loss in central venous 
volume and marked increase in vascular resistance well 
and can develop cardiac failure, marked hypotension, 
cardiac arrhythmias, and even cardiac arrest. Even pa-
tients with more resilient cardiac function will sometimes 
require the infusion of large volumes of fluid (or blood 
products) into the central venous system in order to 
compensate for the marked fall in preload. The penalty 
for this is severe fluid overload at the time of liver 
revascularization when normal venous return is restored. 3 
The occlusion of portal venous outflow is tolerated 
to quite variable degrees as well. Clamping the portal 
vein in the normal dog results in the death of the animal 
within 20 to 30 minutes. '2. '3 Cirrhotic dogs, however, 
can tolerate portal vein clamping for over 1 hour. 14 
Clamping the portal vein in normal man causes fewer 
problems, either because of a more extensive collateral 
network or because of the normal lack of bacterial flora 
in human portal blood. '5,16 Even so, the presence of 
portal hypertension and extensive collateral circulation 
in humans with cirrhosis probably provides an advantage 
similar to that in the canine cirrhosis model. 3 This has 
been particularly evident when long periods (greater 
than 1 hour) of portal occlusion have been necessary in 
patients without portal hypertension, such as those with 
primary malignancies. The degree of gut swelling and 
petechial hemorrhage in the bowel wall has been much 
more severe than that seen in cirrhotics. Frank gastroin-
testinal hemorrhage has not been an infrequent occur-
rence in this setting. 
In the normal dog model, various methods are used 
to keep portal occlusion times as brief as possible. These 
include the classic method of end-to-side portacaval 
shunt combined with a femoral-to-jugular venous bypass 
cannula l2,13 or the use of the "cuff" technique for 
vascular anastomoses originally used by Kamada 17 in 
rats and employed for the normal dog model by 
Monden. 's 
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The original human trials at Denver involved the use 
of venous bypasses in anticipation of problems similar 
to those seen in dogs. 19 But the inordinate incidence of 
embolic phenomena accompanying the use of passive 
shunts led to their abandonment when certainty evolved 
that humans tolerated the an hepatic phase without 
venous decompression much better than dogs. 15. 16 Caine 
has selectively used partial cardiopulmonary bypass in 
an attempt to support patients during the anhepatic 
phase, with varying degrees of success. 20 
A trial of venous bypass using a conventional cardiac 
bypass apparatus was undertaken in Pittsburgh in the 
summer of 1982. Although physiologic advantages during 
the anhepatic phase were quite evident, these were 
outweighed by the severe penalty imposed by the need 
for anticoagulation. This is graphically demonstrated in 
Table 5. Attempts at minimizing the use of heparin 
provided no improvements and the technique was soon 
abandoned. 
But the need for some sort of bypass technique 
remained all too evident by the recurring nightmares of 
the anhepatic phase in a number of patients. Hence, a 
trial of a method that would not require the use of 
systemic anticoagulation was undertaken in the labora-
tory using the normal dog model. The success of these 
experiments, as mentioned earlier, was reported by 
Denmark9 and the initial clinical experience presented 
by Griffith. 10 
Hemodynamic Advantages 
The data presented in the current study demonstrate 
the degree to which normal physiology is restored by 
the use of a venous bypass system. Cardiac filling 
pressures (as measured by a pulmonary artery catheter) 
are supported, and although the cardiac index falls, it 
does so to a much lesser degree than it does without 
bypass and apparently as an appropriate response to 
decreased demand. This latter contention is supported 
by the observation that at the same time that cardiac 
output has fallen, oxygen consumption also decreases 
while the mixed venous oxygen content does not change 
significantly. One possible explanation for this is the 
removal of the liver, a large metabolic machine, from 
the system. But in addition, the patient's core tempera-
ture falls significantly, further lowering metabolic de-
mand. This fall in temperature has been reported be-
fore. 21 It was attributed to a variety of causes in the 
previous report, including long operating times, the 
presence of the cold (4-1O°C) donor liver in the abdomen 
while the vascular anastomoses were completed, and the 
revascularization of the donor liver when cold preser-
vation solution is flushed out of the liver and into the 
systemic circulation by the restored blood flow. The 
technique of venous bypass used currently is a closed 
system without a heat exchanger in the circuit. Additional 
cooling of blood undoubtedly occurs as it passes through 
the bypass circuit. Patient core temperature falls contin-
uously during the bypass phase and reaches a nadir just 
after liver revascularization. 
The high volume of blood returned to the heart from 
the venous beds that otherwise would be obstructed is 
further evidenced by the high flow rates obtained in the 
bypass circuits. The mean flow for all patients of 2.77 
(±0.827) L/min represents 55% of the mean cardiac 
output obtained for these patients during the bypass 
phase. 
Renal Function 
The smaller increase in serum creatmme level and 
the virtual elimination of the requirement for hemodi-
alysis during the early recovery phase in the bypass 
group is encouraging. Previous difficulties, evident in 
the current study by the mean postoperative serum 
creatinine in the non-bypass group of 3.0 (±2.7) mg/dl 
and by the requirement among six patients (without 
overt renal dysfunction before surgery) for hemodialysis 
during the first week following transplantation, are un-
doubtedly related to renal damage occurring primarily 
during the anhepatic phase when the suprarenal vena 
cava is completely occluded. 
Blood Use 
The lower blood use documented since routine venous 
bypass was instituted is explained by several factors. 
The most important results from the complete lack of 
venous hypertension in the systemic and splanchnic 
beds during the anhepatic phase. Without bypass, this 
hypertension continues to increase and hemorrhage can 
accelerate markedly during the anhepatic phase. The 
bypass also allows for a certain period of time (15-60 
minutes) of meticulous effort at hemostasis in the hepatic 
bed after the liver is out of the way. 
Length of Postoperative Recovery 
The use of bypass had no effect on the length of 
hospital stay. This is true even if one eliminates from 
consideration all patients whose recovery was compli-
cated by the necessity for a second or third transplant. 
A bias may be present in these figures since the routine 
monitoring of daily cyclosporine blood levels was insti-
tuted after the introduction of venous bypass for all 
adult recipients. These blood levels demonstrated sur-
prisingly variable cyclosporine absorption, which neces-
sitated prolonged hospital stays for a number of patients 
who might otherwise have been discharged earlier in the 
pre-bypass era. 
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Mortality and Survival 
An examination of Figure I reveals that although 
intraoperative mortality and the postoperative mortality 
up through the first 30 days is markedly less in the 
bypass group, by 90 days this difference is no longer 
significant. The reason for this apparent paradox is 
revealed by Figures 2, 3, and 4. Four of 13 patients in 
the high-risk group (Status 3) who were not bypassed 
died in the operating room in contrast to no operative 
deaths in the bypass Status 3 group. At 30 days, the 
improved survival continued but was overshadowed by 
a markedly increased mortality in the bypass group 
during the next 60 days when compared to the non-
bypass group. Seven of these 13 bypass patients required 
retransplantation, two in whom rejection followed pe-
riods of satisfactory liver function, the other five without 
every obtaining satisfactory hepatic graft function. Two 
of these patients died before 30 days, the other five 
between 30 and 90 days. In the non-bypass group, two 
patients required retransplantation, both of whom sub-
sequently died. More importantly, only two of the 
bypass patients were classified Status 3 because of extreme 
technical considerations and these are the only two 
survivors from this category. In contrast, four of the 13 
non-bypass Status 3 patients were so categorized for 
technical concerns. Three died during surgery and the 
fourth 2 days later. 
The causes of death among those in both groups who 
survived beyond the first 2 weeks after surgery are 
virtually indistinguishable. All had severe hepatic dys-
function and developed sepsis with subsequent multiple 
organ failure. Overall, this is an extremely high-risk 
group in whom the application of venous bypass results 
in improvements in early survival but appears to have 
little impact on the long-term results. An extremely 
important exception to this conclusion must be made 
in the case of those patients determined to be high risk 
for technical reasons. Both surviving patients in the 
bypass group would almost certainly have been operative 
mortalities without the use of bypass. In fact, in the pre-
bypass era, one of these patients would have been 
excluded from candidacy for liver transplantation by 
virtue of having a known portal vein thrombosis. 
Complications 
No pulmonary emboli or deep venous thromboses 
related to the bypass procedure have occurred. Wound 
seromas or hematomas in the groin or axilla have 
developed in six patients. All of these collections resolved 
spontaneously, two following drainage. During surgery, 
no changes in blood coagulation profiles attributable to 
bypass have been seen. 
Recent experience reveals that patients with acute 
Budd-Chiari syndrome are probably not candidates for 
venous bypass. In two recent cases, attempts at throm-
bectomy of the clotted portal and vena caval systems 
followed by establishment of bypass resulted in subop-
timal flows in the bypass circuit. In addition, the risk 
for embolizing preformed thrombus material was rec-
ognized to be quite high. Attempts at bypass were 
abandoned in both of these cases and the anhepatic 
phase proceeded without incidence. 
Other Considerations 
Some of the most important advantages of the venous 
bypass, however, are not demonstrable by the strict 
analysis of physiologic and survival data. Many situations 
arise in which portal and caval venous occlusion times 
must be extended beyond the normal 60 to 90 minutes 
usually felt acceptable without bypass techniques. This 
includes any patient in whom the normal, careful, 
meticulous dissection during the recipient hepatectomy 
is impossible, and removal of the liver can be accom-
plished safely only by immediate and complete devas-
cularization of the organ, followed by rapid resection. 
Hemostasis in the bed is then obtained during the 
anhepatic phase, and may require an hour or more of 
intense effort which, if accompanied by increasing portal 
and caval venous hypertension, may prove fruitless, 
even dangerous. The bypass system in this situation 
allows for a period of careful and deliberate hemostasis 
while keeping the venous beds decompressed and main-
taining central venous pressures. It also allows time for 
careful preparation of vessels for anastomoses, including 
dissecting out a usable recipient hepatic artery and portal 
vein if this were not possible before complete hepatec-
tomy. Finally, the bypass removes a great deal of pressure 
from the surgeon performing the vascular anastomoses 
since the onus of completing them quickly and yet 
accurately is somewhat lessened. This offers particular 
advantages in a training situation. 
Future Outlook 
In general, pediatric patients have fared much better 
than have adults during the anhepatic phase of orthotopic 
liver grafting. Nevertheless, a method of venous bypass 
for the small patient would offer distinct advantages in 
a number of high-risk situations. Application of the 
apparatus currently in use is hindered by the lower limit 
of bypass flow (1000 ml/min) required to eliminate the 
possibility of thrombus formation. In certain situations, 
the disadvantages of systemic heparinization of the 
recipient may be overshadowed by the life-sustaining 
support of a venous bypass. In addition, the laboratory 
experience that defined the safety of the lower limit of 
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bypass flow was all obtained without the use of heparin-
bonded cannulae, tubing, or pump heads. Work is in 
progress that may redefine the lower limit of safe bypass 
flow and thus make venous bypass available in pediatric 
patients. 
Last, although the final impact of venous bypass alone 
has yet to be determined, its routine use has significantly 
lowered the early mortality which, in the past, has often 
been associated with a difficult intraoperative course. 
The fact that its overall impact is not greater underscores 
the continuing need for better immunosuppression and 
better definition of the overwhelming risk factors in 
recipients. 
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DISCUSSION 
DR. WILLIAM V. McDERMOTT, JR. (Boston, Massachusetts): First I 
would like to congratulate the American Surgical Association on its 
perception and recognition of excellence. 
Before commenting directly on this excellent report from Pittsburgh 
of an enormous investment of time and effort, I would like to express 
the great appreciation of our liver transplant team at the New England 
Deaconess Hospital to Drs. Shaw, Starzl, and their associates for the 
tremendous assistance and advice that they provided us during the 
phase of training and orchestration of our liver transplant program, 
which is so vital to successful initiation of such a program. 
Above and beyond the call of duty, both Dr. Shaw and Dr. Starzl 
came to Boston on the occasion of our first transplant a year ago for 
support and advice, which to us was a remarkable evidence of 
collegiality in the world of surgery. 
With these initial comments, I would like to reemphasize the 
important role that venovenous bypass, as you have heard described, 
plays in the orderly completion of the complex set of technical 
maneuvers required in orthotopic transplantation. 
During the past year, we have performed 12 orthotopic transplants, 
using the venovenous bypass. Early in our experience, the bypass was 
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abandoned in one of the operations because of technical problems; 
and in contrast to all the other cases, obvious hemodynamic problems 
developed, with hypotension, with a fall in the cardiac output to 0.9 
I/min during the anhepatic phase; there was also vigorous retroperitoneal 
bleeding, and a significant delay in graft function after surgery, all of 
which. anecdotally at least, we attributed to the nonuse of the bypass. 
Complications of the venovenous bypass have been, so far, limited 
to the development of iliofemoral thrombosis in two patients in our 
early experience, a problem that has been since obviated by technical 
modifications in the insertion of the Gott shunt entirely through a 
previously dilated saphenous vein. Routine postoperative Doppler 
studies since then have shown no further venous thrombotic problems. 
Our impression, therefore, in these initial 12 cases would confirm 
the much larger experience described by Dr. Shaw, that the venovenous 
bypass maintains a stable hemodynamic state during the anhepatic 
phase, is critical in the reperfusion phase of hepatic implantation and 
contributes significantly to the early postoperative function of the 
transplanted liver. 
In closing, we are all in debt to the tremendous contributions of Dr. 
Starzl, Dr. Shaw, and their colleagues during this period of development 
of what I think is now a very acceptable addition to our clinical 
surgical armamentarium. 
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DR. B. W. SHAW, JR. (Closing discusison): Dr. McDermott reminded 
me I should speak a little bit about complications. We have not seen 
any evidence of deep venous thrombosis in our patients, and I think 
the reason is because, very early on, rather than doing a cutdown on 
the femoral vein, we used the saphenous vein. It very readily accepts 
in almost all patients a 7-mm Gott shunt. 
And the axillary vein-we have not looked for a deep venous 
thrombosis in the axillary vein, except in two cases of acute arm 
swelling, and in both of those situations we did not have Doppler 
evidence of thrombosis of the axillary vein. There have been no 
instances of pulmonary emboli that we are aware of, and we monitor 
these patients very closely in the operating room for evidence 
of that. 
I might mention that recently we have had occasion to operate on 
two patients with Budd-Chiari, both of whom were female, who had 
complete occlusion of the vena cava for its entire length up to the 
hepatic veins. The latter patient that we did also had a complete 
thrombosis of the portal vein. 
We attempted to use bypass in both of these patients, and I think 
our experience with that leads me to conclude that bypass in the case 
of acute Budd-Chiari should not be used. We essentially went on 
bypass with one patient, and then experienced decrease in flow, which 
led us to take the patient off bypass. In both situations, the sewing in 
of the graft was done without bypass. So I think that acute Budd-
Chiari may be an exception to the routine use of this procedure in all 
adult patients. 
As far as pediatric patients are concerned, there are certainly many 
situations where it would offer an advantage in those patients as well. 
Right now, we are limited by the practicality with the current apparatus. 
The experience in the dog laboratory that defined the lower limit of 
flow as I liter per minute is based on not using any heparin-bonded 
shunts. We simply added the heparin-bonded shunts when we began 
to use it clinically, because it was more convenient, and because we 
thought it might add some measure of safety. 
I think if we can get a heparin-bonded system, which we are now 
working on, that is smaller and will work in children, there are going 
to be a number of pediatric patients who will also benefit from this 
technique. 
